Clinical Trial: Bioavailability Study of XS003 (Nilotinib)

U.S., Aug. 23 -- ClinicalTrials.gov registry received information related to the study (NCT07138352) titled 'Bioavailability Study of XS003 (Nilotinib)' on July 29.

Brief Summary: An open label, single-center, randomized, two-treatment, two-period, two-sequence, single dose, crossover, study under fasted and fed conditions.

Study Start Date: Oct. 03, 2024

Study Type: INTERVENTIONAL

Condition: Cancer

Intervention: DRUG: XS003 under fed and fasted condition

XS003 under fed and fasted condition

Recruitment Status: COMPLETED

Sponsor: Xspray Pharma AB

Published by HT Digital Content Services with permission from Health Daily Digest....